Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • Emerging therapeutic strategies in breast cancer (Oct 2026)
    • The cGAS-STING pathway: DNA sensing in health and disease (Jun 2026)
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles
  • Search Articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
RASA1 regulates the function of lymphatic vessel valves in mice
Philip E. Lapinski, Beth A. Lubeck, Di Chen, Abbas Doosti, Scott D. Zawieja, Michael J. Davis, Philip D. King
Philip E. Lapinski, Beth A. Lubeck, Di Chen, Abbas Doosti, Scott D. Zawieja, Michael J. Davis, Philip D. King
View: Text | PDF
Research Article Vascular biology

RASA1 regulates the function of lymphatic vessel valves in mice

  • Text
  • PDF
Abstract

Capillary malformation–arteriovenous malformation (CM-AVM) is a blood and lymphatic vessel (LV) disorder that is caused by inherited inactivating mutations of the RASA1 gene, which encodes p120 RasGAP (RASA1), a negative regulator of the Ras small GTP-binding protein. How RASA1 mutations lead to the LV leakage defects that occur in CM-AVM is not understood. Here, we report that disruption of the Rasa1 gene in adult mice resulted in loss of LV endothelial cells (LECs) specifically from the leaflets of intraluminal valves in collecting LVs. As a result, valves were unable to prevent fluid backflow and the vessels were ineffective pumps. Furthermore, disruption of Rasa1 in midgestation resulted in LEC apoptosis in developing LV valves and consequently failed LV valvulogenesis. Similar phenotypes were observed in induced RASA1-deficient adult mice and embryos expressing a catalytically inactive RASA1R780Q mutation. Thus, RASA1 catalytic activity is essential for the function and development of LV valves. These data provide a partial explanation for LV leakage defects and potentially other LV abnormalities observed in CM-AVM.

Authors

Philip E. Lapinski, Beth A. Lubeck, Di Chen, Abbas Doosti, Scott D. Zawieja, Michael J. Davis, Philip D. King

×

Figure 3

Induced RASA1-deficient valves are unable to prevent back-leak.

Options: View larger image (or click on image) Download as PowerPoint
Induced RASA1-deficient valves are unable to prevent back-leak.
(A and B...
(A and B) Example of traces of low-pressure (A) and high-pressure (B) back-leak tests performed with LVs from littermate Rasa1fl/fl and Rasa1fl/fl Ubert2cre mice administered tamoxifen 9 weeks previously. Experimental setup was as in valve-closure tests (Figure 2A). Pin was kept constant at 0.5 cm H2O, and Pout was increased from 0.5 to 10 cm H2O in low-pressure back-leak tests or in 10 cm H2O increments to 100 cm H2O in high-pressure back-leak tests. Back-leak of the increased Pout to the upstream vessel lumen was measured using the Psn micropipette. In low-pressure back-leak tests, closure of RASA1-deficient valves was encouraged at the beginning of the Pout ramp by tapping to introduce spikes in intraluminal pressure (asterisk). (C and D) Mean Psn ± SEM at different Pout in low-pressure (C) and high-pressure (D) back-leak tests performed upon valves from littermate Rasa1fl/fl (n = 3) and Rasa1fl/fl Ubert2cre (n = 7) mice administered tamoxifen 9 weeks previously. (E and F) Mean Psn ± SEM at Pout 10 cm H2O in low-pressure back-leak tests (E) and Pout 100 cm H2O in high-pressure back-leak tests (F) performed upon valves from littermate Rasa1fl/fl and Rasa1fl/fl Ubert2cre mice administered tamoxifen at the indicated number of weeks beforehand (n = 6 of each genotype at 1 and 16 weeks; n = 3 Rasa1fl/fl and n = 7 Rasa1fl/fl Ubert2cre mice at 9 weeks after tamoxifen treatment). See also Supplemental Videos 1 and 2, which show valve behavior in low-pressure back-leak tests conducted with Rasa1fl/fl and Rasa1fl/fl Ubert2cre vessels, respectively, 1 week after tamoxifen treatment. **P < 0.0025; ***P < 0.0005; ****P < 0.0001, Student’s 2-sample t test.

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts